IGF-1 DES vs PT-141
Head-to-head comparison of IGF-1 DES (Des(1-3) Insulin-like Growth Factor 1) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
| Property | IGF-1 DES | PT-141 |
|---|---|---|
| Category | Growth Hormone | Performance |
| Full Name | Des(1-3) Insulin-like Growth Factor 1 | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 7365 Da | 1,025.2 Da |
| Half-Life | ~20-30 minutes | ~2.7 hours |
| Amino Acids | 67 | 7 |
| Typical Dose | — | 1.75 mg |
| Route | — | SC |
| Purity | >98% | — |
| Studies Count | 65 | 178 |
| Research Status | Active Research | FDA Approved |
IGF-1 DES Benefits
- ✓Highly potent localized muscle growth, enhanced protein synthesis, satellite cell proliferation, does not bind to IGFBPs, rapid onset
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
IGF-1 DES Dosing
50-150 mcg per injection site bilaterally post-workout. 4-6 week cycles due to potency. Multiple daily injections in research.
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
IGF-1 DES Side Effects
- ⚠Hypoglycemia (dose-dependent), localized swelling, shorter duration limits systemic exposure compared to IGF-1 LR3.
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
IGF-1 DES
Missing first three amino acids (Gly-Pro-Glu) eliminates IGFBP binding, resulting in 100% bioavailable IGF-1R stimulation. Activates PI3K/Akt/mTOR for protein synthesis and satellite cell proliferation.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.